Facebook Instagram LinkedIn
    • About Us
      • About MEET Magazines
    List My Business        Advertise
    MEET Magazines
    • Home
    • Subscribe
    • Magazines
      • MEET Missouri
      • MEET Kansas
      • MEET Med
    • Articles By Topic
    • Digital Flipbooks
    • Upcoming Events
    ➤ Find Suppliers
    0 Shopping Cart
    MEET Magazines
    Home»Topics»General»Amgen Announces New Data Being Presented At ASH 2020
    General

    Amgen Announces New Data Being Presented At ASH 2020

    MEET MagazinesBy MEET MagazinesDecember 3, 2020Updated:April 8, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    American Society of Hematology logo.svg 768x772 1
    Share
    Facebook Twitter LinkedIn Pinterest Email
    Amgen (NASDAQ:AMGN) announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, Dec. 5-8, 2020.

    Amgen will present updated data from its bispecific T cell engager (BiTE®) portfolio in two oral presentations. Data include the first safety and efficacy findings from the ongoing Phase 1 dose escalation study of AMG 701, an investigational half-life extended BiTE immuno-oncology therapy targeting B-cell maturation antigen (BCMA), in patients with heavily pre-treated relapsed/refractory multiple myeloma. Analyses from the BLINCYTO® (blinatumomab) Phase 3 ‘215 study in children with high-risk first relapse of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) will also be presented.

    “Amgen is advancing one of the most robust bispecific pipelines in the industry,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “In 2020 alone, we are presenting first-in-human data for four assets from the BiTE platform, including these data at ASH with our BCMA-targeted half-life extended BiTE therapy AMG 701.”

    Updated progression-free survival and additional MRD-negativity analyses from the KYPROLIS® (carfilzomib) Phase 3 CANDOR study will also be presented.

    Abstracts are available at https://www.hematology.org/meetings/annual-meeting/abstracts. Learn more about Amgen’s development of innovative medicines for novel targets in difficult-to-treat tumors at AmgenOncology.com/medical.

    To register, click here.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleOpen Season Sportsman’s Expo Headed to Kansas in 2021
    Next Article Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
    MEET Magazines
    • Website

    The MEET Magazines include regional and national publications that keep corporate, association, medical, education, independent, and religious meeting and event planners informed about relevant industry suppliers, news, tech innovations, and resources that impact and influence how and where they plan their upcoming company function(s).

    Related Posts

    Twist and Shout! Two Fundraisers for Two Historic Sappington Houses

    May 26, 2023

    The Lake of the Ozarks 26th Annual Spring Harbor Hop

    May 12, 2023

    SAHARA Las Vegas Announces New Security Executives

    May 11, 2023

    Comments are closed.

    For 20+ years, The MEETⓇ Family of Publications has produced regional and national magazines that has kept corporate, association, medical, education, independent, and religious meeting and event planners informed about relevant vendors, industry news, tech innovations, and resources that impact and influence how and where they plan their group business.

    Latest Industry Insights
    • STR Boosts its Predictions for U.S. Hotel Rates in 2023
    • 82% of Surveyed Hotels Report Staffing Shortages
    • New EIC Study Shows Event Industry is Valued at $1.6 Trillion
    • Embrace the Summer Vibes
    • Twist and Shout! Two Fundraisers for Two Historic Sappington Houses
    Quick Links
    • Home
    • Subscribe
    • Upcoming Events
    Our Magazines
    • MEET Missouri
    • MEET Kansas
    • MEET Med
    More Resources
    • Articles By Topic
    • Digital Flipbooks
    • Online Resource Directory
    © 2023 MEET® Family of Publications. All rights reserved. Website managed and developed by PC40

    Type above and press Enter to search. Press Esc to cancel.